Strangvac, a vaccine against equine Strangles, released for sale in Sweden

Report this content

Stockholm, March 23, 2022 - Intervacc announces today that the first batch of Strangvac, a vaccine against equine Strangles, has been released for sale in Sweden.

“Strangvac has now been released and is in stock at our logistics partner in Sweden. The next step is that Strangvac’s product information is registered in the system used by pharmacies around Sweden. This normally goes quickly, but it can take a few days before all the information is visible in the system ", explains Andreas Johansson, logistics manager at Intervacc.

“We have passed many milestones along the way in the development of a vaccine against equine Strangles, going through the approval and manufacturing process, and we are now at the marketing launch. When Strangvac is now released for sale, we take the step into a new phase. It feels fantastic!” comments Andreas Andersson, Chief Executive Officer of Intervacc.

For more information please contact:  

Andreas Andersson, CEO

Phone: +46-8-120 10 601, cell +46-73-335 99 70

E-mail: andreas.andersson@intervacc.com

 

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on March 23, 2022.

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

 

About equine strangles

Equine strangles, caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. Streptococcus equi invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

Subscribe

Media

Media

Documents & Links

Quotes

We have passed many milestones along the way in the development of a vaccine against equine Strangles, going through the approval and manufacturing process, and we are now at the marketing launch. When Strangvac is now released for sale, we take the step into a new phase. It feels fantastic!
CEO, Andreas Andersson